| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Nrx Pharmaceuticals, Inc. (NRXP) has 0 insiders with recent SEC Form 4 filings, including 7 buys and 10 sells. NRXP is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 25, 2022 | Van Voorhees Seth | Chief Financial Officer | Buy | 16,337 | $1.11 | $18,215.23 | +90.4% | -9.6% | -72.7% | |
| Nov 18, 2022 | Hurvitz Chaim | Director | Buy | 500,000 | $1.03 | $514,905.08 | +66.9% | -5.3% | -72.9% | |
| Nov 17, 2022 | Javitt Daniel C.75 | 10% Owner | Sell | 166,737 | $1.03 | $171,138.22 | -0.9% | -12.3% | -74.6% | |
| Nov 11, 2022 | Javitt Daniel C.75 | 10% Owner | Sell | 49,200 | $1.01 | $49,509.96 | -0.5% | +13.0% | -67.0% | |
| Jul 29, 2022 | Javitt Daniel C.75 | 10% Owner | Sell | 784,063 | $1.01 | $791,433.19 | -7.4% | -0.4% | -55.1% | |
| Jun 7, 2022 | Javitt Daniel C.75 | 10% Owner | Sell | 445,712 | $0.68 | $303,909.59 | -1.2% | +1.6% | -19.2% | |
| Jun 1, 2022 | Javitt Jonathan C62 | Chief Scientist | Buy | 100,000 | $58.00 | $5,800,000.00 | +215.8% | +13.7% | +27.6% | |
| Sep 15, 2021 | Besthof Robert | Chief Comm. &Patient Officer | Sale+OE | 40,000 | $11.76 | $470,400.00 | -62.8% | -52.4% | -93.2% | |
| Aug 23, 2021 | Daigneault Alessandra | General Counsel &Secretary | Sale+OE | 33,715 | $13.11 | $442,003.65 | -100% | -67.0% | -94.8% | |
| Mar 13, 2020 | Polar Asset Management Partners Inc.72 | 10% Owner | Sell | 29,464 | $10.60 | $312,318.40 | -5.7% | - | - |